X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Fresenius Kabi Onco. Fact Sheet, Fresenius Kabi Onco. Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Fresenius Kabi Onco. Fact Sheet   (DBPH)

Here is the latest financial fact sheet of Fresenius Kabi Onco.. For more details, see the Fresenius Kabi Onco. quarterly results and Fresenius Kabi Onco. share price and chart. For a sector overview, read our pharmaceuticals sector report.

FRESENIUS KABI ONCO. Price History

Price Rs 132.5
Mkt Cap Rs m 20,958
Vol '000 91.5
P/E X 22.1
P/CF X 19.7
EPS (TTM) Rs 6.0
% ch % 0.3
No. of shares m 158.23
% ch week % 0.4
% ch 1-mth % 1.9
% ch 12-mth % 20.1
52 week H/L Rs 161.4/93.1
(As on Jan 2, 2014 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

FRESENIUS KABI ONCO. Financials

No. of Mths
Year Ending
12
Mar-09
*
12
Mar-10
*
12
Mar-11
12
Mar-12
12
Mar-13
5-Yr Chart
Click to enlarge
FRESENIUS KABI ONCO. EQUITY SHARE DATA
High Rs81163194165176 
Low Rs2935828279 
Sales per share (Unadj.) Rs19.730.226.133.337.7 
Earnings per share (Unadj.) Rs-9.2-2.13.13.25.1 
Diluted earnings per shareRs-9.2-2.13.13.25.1 
Cash flow per share (Unadj.) Rs-7.4-0.14.24.76.7 
Dividends per share (Unadj.) Rs00000 
Adj. dividends per shareRs0.000.000.000.000.00 
Dividend yield (eoy) %00000 
Book value per share (Unadj.) Rs17.815.734.237.542.5 
Adj. book value per shareRs17.815.734.237.542.5 
Shares outstanding (eoy) m158.23158.23158.23158.23158.23 
Bonus/Rights/Conversions  PI---- 
Price / Sales ratio x2.83.35.33.73.4 
Avg P/E ratio x-6.0-47.044.338.425.0 
P/CF ratio (eoy) x-7.4-1,103.233.026.118.9 
Price / Book Value ratio x3.16.34.03.33.0 
Dividend payout %00000 
Avg Mkt Cap Rs m8,70315,66521,83619,54120,135 
No. of employees `0000.80.91.11.11.2 
Total wages/salary Rs m1,008695561610703 
Avg. sales/employee Rs Th3,789.65,088.43,649.64,784.55,176.2 
Avg. wages/employee Rs Th1,222.9738.9496.1553.9610.4 
Avg. net profit/employee Rs Th-1,772.0-354.9435.4462.7699.6 
FRESENIUS KABI ONCO. INCOME DATA
Net Sales Rs m3,1234,7834,1285,2685,963 
Other income Rs m223140592918 
Total revenues Rs m3,3464,9234,1875,2975,981 
Gross profit Rs m-1,2342277376591,430 
Depreciation Rs m282319169240258 
Interest Rs m291322-47177-26 
Profit before tax Rs m-1,585-2756732721,216 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m153027445-68 
Tax Rs m2859208208342 
Profit after tax Rs m-1,460-334492509806 
Gross profit margin %-39.54.717.812.524.0 
Effective tax rate %-1.8-21.430.876.328.1 
Net profit margin %-46.8-7.011.99.713.5 
FRESENIUS KABI ONCO. BALANCE SHEET DATA
Current assets Rs m3,5635,4205,4524,6795,102 
Current liabilities Rs m3,5444,5963,8382,0902,385 
Net working cap to sales %0.617.239.149.245.6 
Current ratio x1.01.21.42.22.1 
Inventory Days Days166187183129150 
Debtors Days Days11798156140113 
Net fixed assets Rs m4,8975,2803,5394,4535,148 
Share capital Rs m158158158158158 
"Free" reserves Rs m2,6422,3092,4695,7506,556 
Net worth Rs m2,8112,4825,4135,9266,732 
Long term debt Rs m2,0163,602952952952 
Total assets Rs m8,53710,78410,5929,21310,388 
Interest coverage x-4.40.1-13.42.5-45.8 
Debt to equity ratio x0.71.50.20.20.1 
Sales to assets ratio x0.40.40.40.60.6 
Return on assets %-13.7-0.14.27.47.5 
Return on equity %-51.9-13.49.18.612.0 
Return on capital %-23.60.810.313.014.6 
Exports to sales %59.174.280.877.274.5 
Imports to sales %16.315.819.318.724.8 
Exports (fob) Rs m1,8463,5513,3354,0694,441 
Imports (cif) Rs m5087547969861,477 
Fx inflow Rs m1,9573,6103,3614,0725,298 
Fx outflow Rs m9089559911,2501,772 
Net fx Rs m1,0492,6542,3702,8223,525 
FRESENIUS KABI ONCO. CASH FLOW
From Operations Rs m -1,867 -724 500 1,743 1,274 
From Investments Rs m 535 -661 -1,157 168 -1,204 
From Financial Activity Rs m 1,409 1,504 492 -1,965 -196 
Net Cashflow Rs m 77 120 -165 -54 -126 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 81.0%
Indian inst/Mut Fund 0.3%
FIIs 9.6%
ADR/GDR 0.0%
Free float 9.1%
Shareholders 42,599
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B-310, Som Datt Chambers - 1, Bhikaji Cama Place, New Delhi -110 066
E-MAIL complianceofficer.india@fresenius-kabi.com WEB www.fresenius-kabi-oncology.com
TELEPHONE (011) 2610 5570 FAX (011) 2619 5965
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT MCS Limited, F-65, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi-20
AUDITOR G. Basu & Co.
CHM: Rakesh Bhargava COMP SEC: Nikhil Kulshreshtha YEAR OF INC: 2004 BSE CODE: 532545 FV (Rs): 1 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   FULFORD INDIA  DR. REDDYS LAB  ALKEM LABORATORIES  J.B.CHEMICALS  DIVIS LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   FULFORD INDIA  DR. REDDYS LAB  ALKEM LABORATORIES  J.B.CHEMICALS  DIVIS LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - MYLAN COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS